Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 4/2015

01.04.2015 | Original Article - Clinical Oncology

The prognostic significance of p53 expression in gastric cancer: a meta-analysis

verfasst von: Kongkong Wei, Lei Jiang, Yaoyao Wei, Yufeng Wang, Xuankun Qian, Qiang Dai, Quanlin Guan

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Objective

This meta-analysis was conducted to quantitatively assess the prognostic significance of p53 expression in gastric cancer patients.

Methods

A systematic literature search was conducted to identify eligible studies in PubMed and Embase. The pooled hazard ratios (HRs) or odds ratios (ORs) with their corresponding 95 % confidence intervals (95 % CIs) were used to estimate the effect sizes. Moreover, meta-regression analysis and subgroup analysis were carried out.

Results

A total of 34 studies comprising 6,599 patients were subjected to final analysis. Positive/high p53 expression was significantly associated with poorer overall survival (HR 1.56, 95 % CI 1.23–1.98) and disease-specific survival (HR 1.52, 95 % CI 1.35–1.73). The results also indicated that positive/high p53 expression was significantly associated with gender (OR 1.26, 95 % CI 1.09–1.45), Lauren’s classification (OR 1.68, 95 % CI 1.23–2.29), the depth of invasion (OR 0.68, 95 % CI 0.56–0.83), lymph node metastasis (OR 1.56, 95 % CI 1.23–1.97), TNM stage (OR 0.57, 95 % CI 0.47–0.69), vascular invasion (OR 1.51, 95 % CI 1.18–1.92) and lymphatic invasion (OR 1.38, 95 % CI 1.11–1.72), but not with Bormann type (OR 1.24, 95 % CI 0.91–1.70), grade of differentiation (OR 1.08, 95 % CI 0.82–1.44) or distant metastasis (OR 1.37, 95 % CI 0.92–2.03).

Conclusions

This meta-analysis suggests positive/high p53 expression may be a useful biomarker to predict a poorer prognosis for patients with gastric cancer.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Al-Moundhri MS et al (2005) The prognostic significance of p53, p27 kip1, p21 waf1, HER-2/neu, and Ki67 proteins expression in gastric cancer: a clinicopathological and immunohistochemical study of 121 Arab patients. J Surg Oncol 91:243–252CrossRefPubMed Al-Moundhri MS et al (2005) The prognostic significance of p53, p27 kip1, p21 waf1, HER-2/neu, and Ki67 proteins expression in gastric cancer: a clinicopathological and immunohistochemical study of 121 Arab patients. J Surg Oncol 91:243–252CrossRefPubMed
Zurück zum Zitat Anderson C, Nijagal A, Kim J (2006) Molecular markers for gastric adenocarcinoma. Mol Diagn Ther 10:345–352CrossRefPubMed Anderson C, Nijagal A, Kim J (2006) Molecular markers for gastric adenocarcinoma. Mol Diagn Ther 10:345–352CrossRefPubMed
Zurück zum Zitat Baas IO, Mulder JWR, Offerhaus GJA, Vogelstein B, Hamilton SR (1994) An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 172:5–12CrossRefPubMed Baas IO, Mulder JWR, Offerhaus GJA, Vogelstein B, Hamilton SR (1994) An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 172:5–12CrossRefPubMed
Zurück zum Zitat Bani-Hani KE, Almasri NM, Khader YS, Sheyab FM, Karam HN (2005) Combined evaluation of expressions of cyclin E and p53 proteins as prognostic factors for patients with gastric cancer. Clin Cancer Res 11:1447–1453CrossRefPubMed Bani-Hani KE, Almasri NM, Khader YS, Sheyab FM, Karam HN (2005) Combined evaluation of expressions of cyclin E and p53 proteins as prognostic factors for patients with gastric cancer. Clin Cancer Res 11:1447–1453CrossRefPubMed
Zurück zum Zitat Bataille F et al (2003) Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer. Mol pathol 56:286–292CrossRefPubMedCentralPubMed Bataille F et al (2003) Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer. Mol pathol 56:286–292CrossRefPubMedCentralPubMed
Zurück zum Zitat Begg CB (1988) Publication bias: a problem in interpreting medical data. J R Stat Soc A 151:419–463CrossRef Begg CB (1988) Publication bias: a problem in interpreting medical data. J R Stat Soc A 151:419–463CrossRef
Zurück zum Zitat Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101CrossRefPubMed Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101CrossRefPubMed
Zurück zum Zitat Bertuccio P et al (2009) Recent patterns in gastric cancer: a global overview. Int J Cancer 125:666–673CrossRefPubMed Bertuccio P et al (2009) Recent patterns in gastric cancer: a global overview. Int J Cancer 125:666–673CrossRefPubMed
Zurück zum Zitat Bria E et al (2013) A clinical–biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status. Ann Oncol 24:693–701CrossRefPubMed Bria E et al (2013) A clinical–biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status. Ann Oncol 24:693–701CrossRefPubMed
Zurück zum Zitat Chang F, Syrjänen S, Syrjänen K (1995) Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 13:1009–1022PubMed Chang F, Syrjänen S, Syrjänen K (1995) Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 13:1009–1022PubMed
Zurück zum Zitat Chen M, Huang J, Zhu Z, Zhang J, Li K (2013) Systematic review and meta-analysis of tumor biomarkers in predicting prognosis in esophageal cancer. BMC Cancer 13:539CrossRefPubMedCentralPubMed Chen M, Huang J, Zhu Z, Zhang J, Li K (2013) Systematic review and meta-analysis of tumor biomarkers in predicting prognosis in esophageal cancer. BMC Cancer 13:539CrossRefPubMedCentralPubMed
Zurück zum Zitat Cordon-Cardo C et al (1994) p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer 56:347–353CrossRefPubMed Cordon-Cardo C et al (1994) p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer 56:347–353CrossRefPubMed
Zurück zum Zitat De Angelis R et al (2014) Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE–5-a population-based study. Lancet Oncol 15:23–34CrossRefPubMed De Angelis R et al (2014) Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE–5-a population-based study. Lancet Oncol 15:23–34CrossRefPubMed
Zurück zum Zitat De Dosso S et al (2013) ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy. Cancer Chemother Pharmacol 72:159–165CrossRefPubMed De Dosso S et al (2013) ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy. Cancer Chemother Pharmacol 72:159–165CrossRefPubMed
Zurück zum Zitat Diez M et al (2000) P53 protein expression in gastric adenocarcinoma. Negative predictor of survival after postoperative adjuvant chemotherapy. Anticancer Res 20:3929–3933PubMed Diez M et al (2000) P53 protein expression in gastric adenocarcinoma. Negative predictor of survival after postoperative adjuvant chemotherapy. Anticancer Res 20:3929–3933PubMed
Zurück zum Zitat Drebber U et al (2008) The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation. Oncol Rep 19:1477–1483PubMed Drebber U et al (2008) The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation. Oncol Rep 19:1477–1483PubMed
Zurück zum Zitat Efeyan A, Serrano M (2007) p53: guardian of the genome and policeman of the oncogenes. Cell Cycle (Georgetown, Tex) 6:1006–1010CrossRef Efeyan A, Serrano M (2007) p53: guardian of the genome and policeman of the oncogenes. Cell Cycle (Georgetown, Tex) 6:1006–1010CrossRef
Zurück zum Zitat Fenoglio-Preiser CM, Wang J, Stemmermann GN, Noffsinger A (2003) TP53 and gastric carcinoma: a review. Hum Mutat 21:258–270CrossRefPubMed Fenoglio-Preiser CM, Wang J, Stemmermann GN, Noffsinger A (2003) TP53 and gastric carcinoma: a review. Hum Mutat 21:258–270CrossRefPubMed
Zurück zum Zitat Fondevila C et al (2004) p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer 90:206–215CrossRefPubMedCentralPubMed Fondevila C et al (2004) p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer 90:206–215CrossRefPubMedCentralPubMed
Zurück zum Zitat Fu H-L, Shao L, Wang Q, Jia T, Li M, Yang D-P (2013) A systematic review of p53 as a biomarker of survival in patients with osteosarcoma. Tumor Biol 34:3817–3821CrossRef Fu H-L, Shao L, Wang Q, Jia T, Li M, Yang D-P (2013) A systematic review of p53 as a biomarker of survival in patients with osteosarcoma. Tumor Biol 34:3817–3821CrossRef
Zurück zum Zitat Gabbert HE, Muller W, Schneiders A, Meier S, Hommel G (1995) The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer 76:720–726CrossRefPubMed Gabbert HE, Muller W, Schneiders A, Meier S, Hommel G (1995) The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer 76:720–726CrossRefPubMed
Zurück zum Zitat Gurel S et al (1999) Expression of p53 protein and prognosis in gastric carcinoma. J Int Med Res 27:85–89PubMed Gurel S et al (1999) Expression of p53 protein and prognosis in gastric carcinoma. J Int Med Res 27:85–89PubMed
Zurück zum Zitat He MM et al (2014) Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma. World J Gastroenterol 20:264–273CrossRefPubMedCentralPubMed He MM et al (2014) Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma. World J Gastroenterol 20:264–273CrossRefPubMedCentralPubMed
Zurück zum Zitat Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253:49–53CrossRefPubMed Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253:49–53CrossRefPubMed
Zurück zum Zitat Huang T-J, Wang J-Y, Lin S-R, Lian S-T, Hsieh J-S (2001) Overexpression of the c-met protooncogene in human gastric carcinoma-correlation to clinical features. Acta Oncol 40:638–643CrossRefPubMed Huang T-J, Wang J-Y, Lin S-R, Lian S-T, Hsieh J-S (2001) Overexpression of the c-met protooncogene in human gastric carcinoma-correlation to clinical features. Acta Oncol 40:638–643CrossRefPubMed
Zurück zum Zitat Ide M, Kato T, Ogata K, Mochiki E, Kuwano H, Oyama T (2012) Keratin 17 expression correlates with tumor progression and poor prognosis in gastric adenocarcinoma. Ann Surg Oncol 19:3506–3514CrossRefPubMed Ide M, Kato T, Ogata K, Mochiki E, Kuwano H, Oyama T (2012) Keratin 17 expression correlates with tumor progression and poor prognosis in gastric adenocarcinoma. Ann Surg Oncol 19:3506–3514CrossRefPubMed
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90CrossRefPubMed
Zurück zum Zitat Joo YE et al (2002) The role of vascular endothelial growth factor (VEGF) and p53 status for angiogenesis in gastric cancer. Korean J Intern Med 17:211–219PubMed Joo YE et al (2002) The role of vascular endothelial growth factor (VEGF) and p53 status for angiogenesis in gastric cancer. Korean J Intern Med 17:211–219PubMed
Zurück zum Zitat Joypaul BV et al (1994) The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma. Br J Cancer 69:943–946CrossRefPubMedCentralPubMed Joypaul BV et al (1994) The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma. Br J Cancer 69:943–946CrossRefPubMedCentralPubMed
Zurück zum Zitat Juvan R, Hudler P, Gazvoda B, Repse S, Bracko M, Komel R (2007) Significance of genetic abnormalities of p53 protein in Slovenian patients with gastric carcinoma. Croat Med J 48:207–217PubMedCentralPubMed Juvan R, Hudler P, Gazvoda B, Repse S, Bracko M, Komel R (2007) Significance of genetic abnormalities of p53 protein in Slovenian patients with gastric carcinoma. Croat Med J 48:207–217PubMedCentralPubMed
Zurück zum Zitat Kasper HU, Schneider-Stock R, Mellin W, Gunther T, Roessner A (1999) P53-protein accumulation and MDM2-protein overexpression in gastric carcinomas. No apparent correlation with survival. Pathol Res Pract 195:815–820CrossRefPubMed Kasper HU, Schneider-Stock R, Mellin W, Gunther T, Roessner A (1999) P53-protein accumulation and MDM2-protein overexpression in gastric carcinomas. No apparent correlation with survival. Pathol Res Pract 195:815–820CrossRefPubMed
Zurück zum Zitat Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304–6311PubMed Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304–6311PubMed
Zurück zum Zitat Kelley JR, Duggan JM (2003) Gastric cancer epidemiology and risk factors. J Clin Epidemiol 56:1–9CrossRefPubMed Kelley JR, Duggan JM (2003) Gastric cancer epidemiology and risk factors. J Clin Epidemiol 56:1–9CrossRefPubMed
Zurück zum Zitat Kim HS et al (2011) Advanced detection of recent changing trends in gastric cancer survival: up-to-date comparison by period analysis. Jpn J Clin Oncol 41:1344–1350CrossRefPubMed Kim HS et al (2011) Advanced detection of recent changing trends in gastric cancer survival: up-to-date comparison by period analysis. Jpn J Clin Oncol 41:1344–1350CrossRefPubMed
Zurück zum Zitat Kountouras J, Zavos C, Chatzopoulos D (2005) Apoptotic and anti-angiogenic strategies in liver and gastrointestinal malignancies. J Surg Oncol 90:249–259CrossRefPubMed Kountouras J, Zavos C, Chatzopoulos D (2005) Apoptotic and anti-angiogenic strategies in liver and gastrointestinal malignancies. J Surg Oncol 90:249–259CrossRefPubMed
Zurück zum Zitat Ku JH, Byun S-S, Jeong H, Kwak C, Kim HH, Lee SE (2013) The role of p53 on survival of upper urinary tract urothelial carcinoma: a systematic review and meta-analysis. Clin Genitourin Cancer 11:221–228CrossRefPubMed Ku JH, Byun S-S, Jeong H, Kwak C, Kim HH, Lee SE (2013) The role of p53 on survival of upper urinary tract urothelial carcinoma: a systematic review and meta-analysis. Clin Genitourin Cancer 11:221–228CrossRefPubMed
Zurück zum Zitat Kubicka S et al (2002) p53 mutation pattern and expression of c-erbB2 and c-met in gastric cancer: relation to histological subtypes, helicobacter pylori infection, and prognosis. Dig Dis Sci 47:114–121CrossRefPubMed Kubicka S et al (2002) p53 mutation pattern and expression of c-erbB2 and c-met in gastric cancer: relation to histological subtypes, helicobacter pylori infection, and prognosis. Dig Dis Sci 47:114–121CrossRefPubMed
Zurück zum Zitat Lauren P (1965) The two histological main types of gastric carcinoma: diffuse and so-called intestinal type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64:31–49PubMed Lauren P (1965) The two histological main types of gastric carcinoma: diffuse and so-called intestinal type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64:31–49PubMed
Zurück zum Zitat Lazar D et al (2010) The immunohistochemical expression of the p53-protein in gastric carcinomas. Correlation with clinicopathological factors and survival of patients. Rom J Morphol Embryol 51:249–257PubMed Lazar D et al (2010) The immunohistochemical expression of the p53-protein in gastric carcinomas. Correlation with clinicopathological factors and survival of patients. Rom J Morphol Embryol 51:249–257PubMed
Zurück zum Zitat Lee WJ, Shun CT, Hong RL, Wu MS, Chang KJ, Chen KM (1998) Overexpression of p53 predicts shorter survival in diffuse type gastric cancer. Br J Surg 85:1138–1142CrossRefPubMed Lee WJ, Shun CT, Hong RL, Wu MS, Chang KJ, Chen KM (1998) Overexpression of p53 predicts shorter survival in diffuse type gastric cancer. Br J Surg 85:1138–1142CrossRefPubMed
Zurück zum Zitat Lee KE et al (2003) Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer. Jpn J Clin Oncol 33:173–179CrossRefPubMed Lee KE et al (2003) Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer. Jpn J Clin Oncol 33:173–179CrossRefPubMed
Zurück zum Zitat Lehrbach DM, Cecconello I, Ribeiro U Jr, Capelozzi VL, Ab’saber AM, Alves VA (2009) Adenocarcinoma of the esophagogastric junction: relationship between clinicopathological data and p53, cyclin D1 and Bcl-2 immunoexpressions. Arq Gastroenterol 46:315–320CrossRefPubMed Lehrbach DM, Cecconello I, Ribeiro U Jr, Capelozzi VL, Ab’saber AM, Alves VA (2009) Adenocarcinoma of the esophagogastric junction: relationship between clinicopathological data and p53, cyclin D1 and Bcl-2 immunoexpressions. Arq Gastroenterol 46:315–320CrossRefPubMed
Zurück zum Zitat Li M, Brooks CL, Kon N, Gu W (2004) A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol Cell 13:879–886CrossRefPubMed Li M, Brooks CL, Kon N, Gu W (2004) A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol Cell 13:879–886CrossRefPubMed
Zurück zum Zitat Lim BH, Soong R, Grieu F, Robbins PD, House AK, Iacopetta BJ (1996) p53 accumulation and mutation are prognostic indicators of poor survival in human gastric carcinoma. Int J Cancer 69:200–204CrossRefPubMed Lim BH, Soong R, Grieu F, Robbins PD, House AK, Iacopetta BJ (1996) p53 accumulation and mutation are prognostic indicators of poor survival in human gastric carcinoma. Int J Cancer 69:200–204CrossRefPubMed
Zurück zum Zitat Liu XP, Tsushimi K, Tsushimi M, Kawauchi S, Oga A, Furuya T, Sasaki K (2001) Expression of p21(WAF1/CIP1) and p53 proteins in gastric carcinoma: its relationships with cell proliferation activity and prognosis. Cancer Lett 170:183–189CrossRefPubMed Liu XP, Tsushimi K, Tsushimi M, Kawauchi S, Oga A, Furuya T, Sasaki K (2001) Expression of p21(WAF1/CIP1) and p53 proteins in gastric carcinoma: its relationships with cell proliferation activity and prognosis. Cancer Lett 170:183–189CrossRefPubMed
Zurück zum Zitat Liu J et al (2012a) Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis. Eur J Cancer 48:2328–2338CrossRefPubMedCentralPubMed Liu J et al (2012a) Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis. Eur J Cancer 48:2328–2338CrossRefPubMedCentralPubMed
Zurück zum Zitat Maehara Y, Tomoda M, Hasuda S, Kabashima A, Tokunaga E, Kakeji Y, Sugimachi K (1999) Prognostic value of p53 protein expression for patients with gastric cancer: a multivariate analysis. Br J Cancer 79:1255–1261CrossRefPubMedCentralPubMed Maehara Y, Tomoda M, Hasuda S, Kabashima A, Tokunaga E, Kakeji Y, Sugimachi K (1999) Prognostic value of p53 protein expression for patients with gastric cancer: a multivariate analysis. Br J Cancer 79:1255–1261CrossRefPubMedCentralPubMed
Zurück zum Zitat Malats N et al (2005) P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 6:678–686CrossRefPubMed Malats N et al (2005) P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 6:678–686CrossRefPubMed
Zurück zum Zitat Matturri L et al (1998) Prognostic significance of different biological markers (DNA index, PCNA index, apoptosis, p53, karyotype) in 126 adenocarcinoma gastric biopsies. Anticancer Res 18:2819–2825PubMed Matturri L et al (1998) Prognostic significance of different biological markers (DNA index, PCNA index, apoptosis, p53, karyotype) in 126 adenocarcinoma gastric biopsies. Anticancer Res 18:2819–2825PubMed
Zurück zum Zitat Migliavacca M et al (2004) TP53 in gastric cancer: mutations in the l3 loop and LSH motif DNA-binding domains of TP53 predict poor outcome. J Cell Physiol 200:476–485CrossRefPubMed Migliavacca M et al (2004) TP53 in gastric cancer: mutations in the l3 loop and LSH motif DNA-binding domains of TP53 predict poor outcome. J Cell Physiol 200:476–485CrossRefPubMed
Zurück zum Zitat Mrena J, Wiksten JP, Kokkola A, Nordling S, Ristimaki A, Haglund C (2010) COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer. Tumour Biol 31:1–7CrossRefPubMed Mrena J, Wiksten JP, Kokkola A, Nordling S, Ristimaki A, Haglund C (2010) COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer. Tumour Biol 31:1–7CrossRefPubMed
Zurück zum Zitat Mrozek A et al (2003) Combined p53/Bax mutation results in extremely poor prognosis in gastric carcinoma with low microsatellite instability. Cell Death Differ 10:461–467CrossRefPubMed Mrozek A et al (2003) Combined p53/Bax mutation results in extremely poor prognosis in gastric carcinoma with low microsatellite instability. Cell Death Differ 10:461–467CrossRefPubMed
Zurück zum Zitat Ott K et al (2003) Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma. Clin Cancer Res 9:2307–2315PubMed Ott K et al (2003) Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma. Clin Cancer Res 9:2307–2315PubMed
Zurück zum Zitat Pakos EE, Kyzas PA, Ioannidis JP (2004) Prognostic significance of TP53 tumor suppressor gene expression and mutations in human osteosarcoma a meta-analysis. Clin Cancer Res 10:6208–6214CrossRefPubMed Pakos EE, Kyzas PA, Ioannidis JP (2004) Prognostic significance of TP53 tumor suppressor gene expression and mutations in human osteosarcoma a meta-analysis. Clin Cancer Res 10:6208–6214CrossRefPubMed
Zurück zum Zitat Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815–2834CrossRefPubMed Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815–2834CrossRefPubMed
Zurück zum Zitat Peng L, Zhan P, Zhou Y, Fang W, Zhao P, Zheng Y, Xu N (2012) Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis. Mol Biol Rep 39:9473–9484CrossRefPubMed Peng L, Zhan P, Zhou Y, Fang W, Zhao P, Zheng Y, Xu N (2012) Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis. Mol Biol Rep 39:9473–9484CrossRefPubMed
Zurück zum Zitat Pinto-de-Sousa J, Silva F, David L, Leitao D, Seixas M, Pimenta A, Cardoso-de-Oliveira M (2004) Clinicopathological significance and survival influence of p53 protein expression in gastric carcinoma. Histopathology 44:323–331CrossRefPubMed Pinto-de-Sousa J, Silva F, David L, Leitao D, Seixas M, Pimenta A, Cardoso-de-Oliveira M (2004) Clinicopathological significance and survival influence of p53 protein expression in gastric carcinoma. Histopathology 44:323–331CrossRefPubMed
Zurück zum Zitat Potrc S, Gadiijev E, Hajdinjak T, Kavalar R (2007) Clinicopathological and immunohistochemical markers after radical gastrectomy for gastric cancer. Hepatogastroenterology 54:308–314PubMed Potrc S, Gadiijev E, Hajdinjak T, Kavalar R (2007) Clinicopathological and immunohistochemical markers after radical gastrectomy for gastric cancer. Hepatogastroenterology 54:308–314PubMed
Zurück zum Zitat Puhringer-Oppermann F, Stahl M, Keller G, Sarbia M (2006) Lack of prognostic impact of p53 gene mutation and p53 phosphorylation at serine 15 in multimodally treated adenocarcinomas of the gastroesophageal junction. J Cancer Res Clin Oncol 132:433–438CrossRefPubMed Puhringer-Oppermann F, Stahl M, Keller G, Sarbia M (2006) Lack of prognostic impact of p53 gene mutation and p53 phosphorylation at serine 15 in multimodally treated adenocarcinomas of the gastroesophageal junction. J Cancer Res Clin Oncol 132:433–438CrossRefPubMed
Zurück zum Zitat Rivera F, Vega-Villegas ME, López-Brea MF (2007) Chemotherapy of advanced gastric cancer. Cancer Treat Rev 33:315–324CrossRefPubMed Rivera F, Vega-Villegas ME, López-Brea MF (2007) Chemotherapy of advanced gastric cancer. Cancer Treat Rev 33:315–324CrossRefPubMed
Zurück zum Zitat Roviello F, Marrelli D, Vindigni C, De Stefano A, Spina D, Pinto E (1999) P53 accumulation is a prognostic factor in intestinal-type gastric carcinoma but not in the diffuse type. Ann Surg Oncol 6:739–745CrossRefPubMed Roviello F, Marrelli D, Vindigni C, De Stefano A, Spina D, Pinto E (1999) P53 accumulation is a prognostic factor in intestinal-type gastric carcinoma but not in the diffuse type. Ann Surg Oncol 6:739–745CrossRefPubMed
Zurück zum Zitat Sawada T et al (2014) New molecular staging with G-factor supplements TNM classification in gastric cancer: a multicenter collaborative research by the Japan society for gastroenterological carcinogenesis G-project committee. Gastric Cancer. doi:10.1007/s10120-014-0338-2 Sawada T et al (2014) New molecular staging with G-factor supplements TNM classification in gastric cancer: a multicenter collaborative research by the Japan society for gastroenterological carcinogenesis G-project committee. Gastric Cancer. doi:10.​1007/​s10120-014-0338-2
Zurück zum Zitat Sgambato A et al (2000) Loss of p27Kip1 expression is a strong independent prognostic factor of reduced survival in N0 gastric carcinomas. Cancer 89:2247–2257CrossRefPubMed Sgambato A et al (2000) Loss of p27Kip1 expression is a strong independent prognostic factor of reduced survival in N0 gastric carcinomas. Cancer 89:2247–2257CrossRefPubMed
Zurück zum Zitat Solcia E et al (2009) A combined histologic and molecular approach identifies three groups of gastric cancer with different prognosis. Virchows Arch 455:197–211CrossRefPubMed Solcia E et al (2009) A combined histologic and molecular approach identifies three groups of gastric cancer with different prognosis. Virchows Arch 455:197–211CrossRefPubMed
Zurück zum Zitat Song KY, Jung CK, Park WS, Park CH (2009) Expression of the antiapoptosis gene survivin predicts poor prognosis of stage III gastric adenocarcinoma. Jpn J Clin Oncol 39:290–296CrossRefPubMed Song KY, Jung CK, Park WS, Park CH (2009) Expression of the antiapoptosis gene survivin predicts poor prognosis of stage III gastric adenocarcinoma. Jpn J Clin Oncol 39:290–296CrossRefPubMed
Zurück zum Zitat Song J, Su H, Y-y Zhou, L-l Guo (2013) Cyclooxygenase-2 expression is associated with poor overall survival of patients with gastric cancer: a meta-analysis. Dig Dis Sci 59:436–445CrossRefPubMed Song J, Su H, Y-y Zhou, L-l Guo (2013) Cyclooxygenase-2 expression is associated with poor overall survival of patients with gastric cancer: a meta-analysis. Dig Dis Sci 59:436–445CrossRefPubMed
Zurück zum Zitat Soussi T (2000) The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann NY Acad Sci 910:121–137CrossRefPubMed Soussi T (2000) The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann NY Acad Sci 910:121–137CrossRefPubMed
Zurück zum Zitat Steels E et al (2001) Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 18:705–719CrossRefPubMed Steels E et al (2001) Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 18:705–719CrossRefPubMed
Zurück zum Zitat Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16CrossRefPubMedCentralPubMed Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16CrossRefPubMedCentralPubMed
Zurück zum Zitat Toledo F, Wahl GM (2006) Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 6:909–923CrossRefPubMed Toledo F, Wahl GM (2006) Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 6:909–923CrossRefPubMed
Zurück zum Zitat Tsujitani S et al (2012) Relationship between expression of apoptosis-related proteins and the efficacy of postoperative chemotherapy in patients with T3 gastric cancer. Surg Today 42:225–232CrossRefPubMed Tsujitani S et al (2012) Relationship between expression of apoptosis-related proteins and the efficacy of postoperative chemotherapy in patients with T3 gastric cancer. Surg Today 42:225–232CrossRefPubMed
Zurück zum Zitat Wang J et al (2011) p53 status and its prognostic role in extrahepatic bile duct cancer: a meta-analysis of published studies. Dig Dis Sci 56:655–662CrossRefPubMed Wang J et al (2011) p53 status and its prognostic role in extrahepatic bile duct cancer: a meta-analysis of published studies. Dig Dis Sci 56:655–662CrossRefPubMed
Zurück zum Zitat Xiao LJ, Zhao S, Zhao EH, Zheng X, Gou WF, Takano Y, Zheng HC (2013) Clinicopathological and prognostic significance of Ki-67, caspase-3 and p53 expression in gastric carcinomas. Oncol Lett 6:1277–1284PubMedCentralPubMed Xiao LJ, Zhao S, Zhao EH, Zheng X, Gou WF, Takano Y, Zheng HC (2013) Clinicopathological and prognostic significance of Ki-67, caspase-3 and p53 expression in gastric carcinomas. Oncol Lett 6:1277–1284PubMedCentralPubMed
Zurück zum Zitat Xing X, Tang YB, Yuan G, Wang Y, Wang J, Yang Y, Chen M (2013) The prognostic value of E-cadherin in gastric cancer: a meta-analysis. Int J Cancer 132:2589–2596CrossRefPubMed Xing X, Tang YB, Yuan G, Wang Y, Wang J, Yang Y, Chen M (2013) The prognostic value of E-cadherin in gastric cancer: a meta-analysis. Int J Cancer 132:2589–2596CrossRefPubMed
Zurück zum Zitat Yoo C, Noh S, Shin D, Choi S, Min J (2000) Recurrence following curative resection for gastric carcinoma. Br J Surg 87:236–242CrossRefPubMed Yoo C, Noh S, Shin D, Choi S, Min J (2000) Recurrence following curative resection for gastric carcinoma. Br J Surg 87:236–242CrossRefPubMed
Zurück zum Zitat Zafirellis K, Karameris A, Milingos N, Androulakis G (2005) Molecular markers in gastric cancer: can p53 and bcl-2 protein expressions be used as prognostic factors? Anticancer Res 25:3629–3636PubMed Zafirellis K, Karameris A, Milingos N, Androulakis G (2005) Molecular markers in gastric cancer: can p53 and bcl-2 protein expressions be used as prognostic factors? Anticancer Res 25:3629–3636PubMed
Zurück zum Zitat Zha Y, Cun Y, Zhang Q, Li Y, Tan J (2012) Prognostic value of expression of Kit67, p53, TopoIIa and GSTP1 for curatively resected advanced gastric cancer patients receiving adjuvant paclitaxel plus capecitabine chemotherapy. Hepatogastroenterology 59:1327–1332PubMed Zha Y, Cun Y, Zhang Q, Li Y, Tan J (2012) Prognostic value of expression of Kit67, p53, TopoIIa and GSTP1 for curatively resected advanced gastric cancer patients receiving adjuvant paclitaxel plus capecitabine chemotherapy. Hepatogastroenterology 59:1327–1332PubMed
Metadaten
Titel
The prognostic significance of p53 expression in gastric cancer: a meta-analysis
verfasst von
Kongkong Wei
Lei Jiang
Yaoyao Wei
Yufeng Wang
Xuankun Qian
Qiang Dai
Quanlin Guan
Publikationsdatum
01.04.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 4/2015
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-014-1844-7

Weitere Artikel der Ausgabe 4/2015

Journal of Cancer Research and Clinical Oncology 4/2015 Zur Ausgabe

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.